Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is poised for success as they have a strong pipeline and a proprietary, in-house cell-based manufacturing platform that sets them apart from competitors. The company has reported positive revenue growth and net income for the fourth quarter of 2025, and has a strategic roadmap for 2026 that focuses on advancing their platform across multiple diseases. Management's focus on expanding their pipeline through both internal development and strategic partnerships further adds to the company's potential for growth and success.

Bears say

Lineage Cell Therapeutics is facing multiple risks including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks. While the company has shown progress in its partnership with Roche and Genentech and advancements in its AlloSCOPE platform, its limited cash reserves and potential competition in the market for its therapies raise concerns about its ability to sustain its operations and gain market share. Additionally, the company's focus on degenerative diseases, while important, may limit its potential for diversification and growth in the increasingly competitive biotechnology industry.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.